PRESS RELEASE For immediate release DEVONIAN HEATH GROUP INC. TO PARTICIPATE IN RENMARK’S VIRTUAL NON-DEAL ROADSHOW SERIES ON THURSDAY, MAY 13, 2021. QUEBEC, May 11, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical...
Press Releases
DEVONIAN HEALTH GROUP INC. RETAINS RENMARK FINANCIAL COMMUNICATIONS INC. TO PROVIDE INVESTOR RELATIONS SERVICES
PRESS RELEASE For immediate release DEVONIAN HEALTH GROUP INC. RETAINS RENMARK FINANCIAL COMMUNICATIONS INC. TO PROVIDE INVESTOR RELATIONS SERVICES. QUEBEC, April 14, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical...
Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering use of Thykamine™ for the treatment of Cardiovascular Diseases
PRESS RELEASE For immediate release Devonian Health Group Announces Notice of Allowance for a US Patent Application Covering use of Thykamine™ for the treatment of Cardiovascular Diseases. QUEBEC, March 30th , 2021 – Devonian Health Group Inc. (“Devonian” or...
Devonian Health Group provides more details on Previously Announced Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Population with Mild-to-Moderate Atopic Dermatitis and the Grant of Stock Options
PRESS RELEASE For immediate release Devonian Health Group provides more details on Previously Announced Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Population with Mild-to-Moderate Atopic Dermatitis and the Grant of Stock Options....
DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS. QUEBEC, March 5, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...
Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Patients with Mild-to-Moderate Atopic Dermatitis
PRESS RELEASE For immediate release Devonian Health Group Announces Positive Topline Results from Phase 2 Clinical trial of Thykamine™ in Adult Patients with Mild-to-Moderate Atopic Dermatitis. Thykamine™ monotherapy achieved positive results by reaching the...
Devonian Health Group Announces voting results of the Annual General and Special Meeting
PRESS RELEASE For immediate release Devonian Health Group Announces voting results of the Annual General and Special Meeting. QUEBEC, – January 28, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...
DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO A DEBENTURE HOLDER
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO A DEBENTURE HOLDER. QUEBEC, January 22, 2021 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage botanical...
Devonian Health Group Announces Closing of a Private Placement and the Grant of Stock Options
PRESS RELEASE For immediate release Devonian Health Group Announces Closing of a Private Placement and the Grant of Stock Options. Not for distribution to United States newswire services or for dissemination in the United States QUEBEC, December 30, 2020 –...
DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS
PRESS RELEASE For immediate release DEVONIAN ANNOUNCES THE ISSUANCE OF UNITS IN SETTLEMENT OF INTERESTS OWED TO DEBENTURE HOLDERS. QUEBEC City, October 9, 2020 – Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXv: GSD), a clinical stage...